Clinical characteristics at the time of pulmonary arterial hypertension (PAH) diagnosis

Age years52 (17–74)
Female15 (71)
 CML19 (90)
 ALL1 (5)
 Systemic mastocytosis1 (5)
TKI treatment prior to dasatinib
 Imatinib17 (81)
 Nilotinib2 (10)
 None4 (19)
Other oncological treatment
 Hydroxycarbamide17 (81)
 Interferon10 (48)
 Cytarabine5 (24)
 None2 (5)
Delay from dasatinib initiation to PAH diagnosis months42 (8–74)
Dasatinib dose at PAH diagnosis mg·day−1100 (50–140)
NYHA FC I/II/III/IV0/5/10/6 (0/24/48/29)
Pleural effusions13 (62)
Pericardial effusion6 (29)
6MWD m306 (0–660)
BNP ng·L−1163 (49–1635)
PaO2 kPa9.9 (6.3–14)
Haemoglobin g·dL−113.2 (7.9–19)
DLCO % pred63 (41–98)
RAP mmHg6 (3–24)
mPAP mmHg45 (30–70)
PAWP mmHg10 (3–23)
Cardiac output L·min−16.0 (2.3–9.2)
Cardiac index L·min−1·m−23.3 (1.4–4.8)
PVR WU6.1 (3.2–27.3)
SvO2 %65 (44–85)

Data are presented as n, median (range) or n (%). CML: chronic myelogenous leukaemia; ALL: acute lymphoblastic leukaemia; TKI: tyrosine kinase inhibitor; NYHA FC: New York Heart Association functional class; 6MWD: 6-min walk distance; BNP: brain natriuretic peptide; PaO2: arterial oxygen tension; DLCO: diffusion capacity of the lung for carbon monoxide; RAP: right atrial pressure; mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; WU: Wood units; SvO2: mixed venous oxygen saturation.